ClinicalTrials.gg
CompletedNCT01163266Updated Dec 18, 2013Results posted

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Depressive Disorder, Major, sponsored by Takeda. Completed at 39 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
462
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
23rd of 54
462 · median 413
Started
2010
with 5 others
Phase 3
31 of 54
1 open now
Registered
14th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 23rd largest by enrollment, is one of 6 that started in 2010, is one of 31 in phase 3, and was the 14th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.

Read the detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine.

The study enrolled 462 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 10 mg
  • Vortioxetine 20 mg
  • Placebo (dummy inactive capsule) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 13 weeks. Participants made 9 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Major Depressive Disorder
  • Depression
  • Melancholia
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suffers from a major depressive episode recurrent as the primary diagnosis according to the American Psychiatric Association , Fourth Edition, Text Revision (DSM-IV-TR) criteria.
  • Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits.
  • Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.

Exclusion criteria

Exclusion Criteria:

  • Has previously participated in a Lu AA21004 clinical study.
  • Has 1 or more the following:

    • Any current psychiatric disorder other than Major Depressive Disorder as defined in the
    • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder defined in the DSM-IV-TR.
    • Diagnosis of alcohol or other substance disorder (except nicotine and caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least years prior to screening (participant must also have negative urine drug screen prior to Baseline).
    • Presence or history of a neurological disorder (including epilepsy)
    • Neurodegenerative disorder.
    • Any Axis II disorder that might compromise the study.
  • Has a thyroid stimulating hormone value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.
  • Has clinically significant abnormal vital signs as determined by the investigator.
  • Has an abnormal .
  • Has an , aspartate aminotransferase or total level greater than 1.5 times the .
  • Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication.
  • Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  • Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  • Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. For the purposes of this protocol the following conditions are considered unstable due to the potential impact on assessment of MDD response: pain disorder, chronic fatigue syndrome, fibromyalgia, and obstructive sleep apnea.
  • Has a significant risk of suicide according to the investigator's opinion.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
462 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matching capsules, orally, once daily for up to 8 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 20 mg

    Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.

    Drug: Vortioxetine

Interventions

  • Encapsulated vortioxetine immediate release tablets

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means are from a mixed model for repeated measurements (MMRM) analysis of covariance (ANCOVA) with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Percentage of Participants With a MADRS Response at Week 8

    Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Baseline and Week 8

  2. Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8

    The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score-by-week as fixed effects.

    Time frame: Week 8

  3. Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects. The HAM-A is a 14 item rating scale to quantify anxiety severity rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56, where lower scores indicate mild severity.

    Time frame: Baseline and Week 8

  4. Percentage of Participants in MADRS Remission at Week 8

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Week 8

  5. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline SDS total score-by-week as fixed effects.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 37 investigative sites in the United States from 15 July 2010 to 17 January 2012.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 10 mgVortioxetine 20 mg
Started157155150
Treated157155150
Completed139124122
Not completed183128
Withdrew: Pretreatment event or adverse event297
Withdrew: Lack of efficacy131
Withdrew: Noncompliance with study drug020
Withdrew: Protocol deviations225
Withdrew: Withdrawal of consent573
Withdrew: Lost to follow-up7710
Withdrew: Other112

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means are from a mixed model for repeated measurements (MMRM) analysis of covariance (ANCOVA) with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score-10.77 ± 0.807-12.96 ± 0.832-14.41 ± 0.845
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.058 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -2.19 · 95% CI -4.45 to 0.08MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline MADRS total score-by-week as fixed effects.
  • Placebo vs Vortioxetine 20 mg · Mixed model for repeated measurements · p = 0.002 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.025, hierarchical testing continues.) · Ls mean difference: -3.64 · 95% CI -5.92 to -1.35MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline MADRS total score-by-week as fixed effects.
SecondaryPercentage of Participants With a MADRS Response at Week 8

Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a MADRS Response at Week 8
percentage of participantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Percentage of Participants With a MADRS Response at Week 828.433.839.2
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.301 · Odds ratio (or): 1.290 · 95% CI 0.796 to 2.093Logistic regression with explanatory variables for treatment and Baseline MADRS score.
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.044 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Odds ratio (or): 1.639 · 95% CI 1.013 to 2.652Logistic regression with explanatory variables for treatment and Baseline MADRS score.
SecondaryMean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8

The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score-by-week as fixed effects.

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8
scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 82.89 ± 0.0902.69 ± 0.0932.59 ± 0.094
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.119 · Ls mean difference: -0.20 · 95% CI -0.45 to 0.05MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline CGI-S score-by-week as fixed effects.
  • Placebo vs Vortioxetine 20 mg · Mixed model for repeated measurements · p = 0.024 · Ls mean difference: -0.29 · 95% CI -0.55 to -0.04MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline CGI-S score-by-week as fixed effects.
SecondaryChange From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20

The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects. The HAM-A is a 14 item rating scale to quantify anxiety severity rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56, where lower scores indicate mild severity.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20
scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20-10.26 ± 1.392-14.55 ± 1.369-17.52 ± 1.331
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.025 · Ls mean difference: -4.29 · 95% CI -8.03 to -0.56MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline MADRS Total score-by-week as fixed effects.
  • Placebo vs Vortioxetine 20 mg · Mixed model for repeated measurements · p = <0.001 · Ls mean difference: -7.26 · 95% CI -10.92 to -3.60MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline MADRS total score-by-week as fixed effects.
SecondaryPercentage of Participants in MADRS Remission at Week 8

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 8
percentage of participantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Percentage of Participants in MADRS Remission at Week 814.221.422.3
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.093 · Odds ratio (or): 1.665 · 95% CI 0.918 to 3.018Logistic regression with explanatory variables for treatment and Baseline MADRS score.
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.059 · Odds ratio (or): 1.779 · 95% CI 0.979 to 3.233Logistic regression with explanatory variables for treatment and Baseline MADRS score.
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline SDS total score-by-week as fixed effects.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-5.86 ± 0.771-7.25 ± 0.747-8.26 ± 0.794
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.183 · Ls mean difference: -1.39 · 95% CI -3.44 to 0.66MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline SDS total score-by-week as fixed effects.
  • Placebo vs Vortioxetine 20 mg · Mixed model for repeated measurements · p = 0.025 · Ls mean difference: -2.40 · 95% CI -4.50 to -0.30MMRM ANCOVA with treatment, center, week, treatment-by-week interaction, baseline SDS total score-by-week as fixed effects.

Adverse events

Collected over A treatment-emergent adverse event is defined as any event whose onset occurs or intensity increases after the first dose of double-blind study medication through 30 days after permanent discontinuation of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/157 (0%)80/157 (51%)
Vortioxetine 10 mg—2/155 (1.3%)103/155 (66.5%)
Vortioxetine 20 mg—0/150 (0%)94/150 (62.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
Kidney infectionInfections and infestations0/1571/1550/150
Suicide attemptPsychiatric disorders0/1571/1550/150
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
NauseaGastrointestinal disorders8/15742/15544/150
HeadacheNervous system disorders17/15724/15524/150
DiarrhoeaGastrointestinal disorders14/15720/15511/150
Dry mouthGastrointestinal disorders15/1577/1557/150
DizzinessNervous system disorders9/15713/1559/150
ConstipationGastrointestinal disorders4/15712/1559/150
Viral upper respiratory tract infectionInfections and infestations9/15710/1555/150
VomitingGastrointestinal disorders3/1579/1558/150
FatigueGeneral disorders9/1579/1550/150
NasopharyngitisInfections and infestations1/1574/1557/150

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean42.3 ± 11.6143.1 ± 12.0443.1 ± 13.0942.8 ± 12.23
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
≤55 years130133124387
>55 years27222675
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Female110118107335
Male473743127
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Hispanic or Latino17101037
Non-Hispanic and non-Latino140145140425
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Caucasian (White, including Hispanic)12010697323
Black374349129
American Indian or Alaska Native0415
Asian0213
Native Hawaiian or Other Pacific Islander0022
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
United States157155150462
Height
Height(cm)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean167.46 ± 9.265166.86 ± 9.199167.92 ± 9.194167.41 ± 9.210
Weight
Weight(kg)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean88.28 ± 23.29089.00 ± 23.07687.08 ± 23.58288.13 ± 23.277

7 further baseline measures are reported on the registry.

08

Study locations

39 sites
  • Anaheim, California, United States
  • Cerritos, California, United States
  • Costa Mesa, California, United States
  • Encino, California, United States
  • Garden Grove, California, United States
  • Irvine, California, United States
  • Pico Rivera, California, United States
  • Riverside, California, United States
  • Colorado Springs, Colorado, United States
  • Norwich, Connecticut, United States
  • Maitland, Florida, United States
  • North Miami, Florida, United States
  • Orange City, Florida, United States
  • Orlando, Florida, United States
  • St. Petersburg, Florida, United States
  • Smyrna, Georgia, United States
  • Chicago, Illinois, United States
  • Joliet, Illinois, United States
  • Skokie, Illinois, United States
  • Wichita, Kansas, United States
  • Lake Charles, Louisiana, United States
  • Worcester, Massachusetts, United States
  • St. Charles, Missouri, United States
  • St. Louis, Missouri, United States
  • Willingboro, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Cinti, Ohio, United States
  • Dayton, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Portland, Oregon, United States
  • Norristown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Irving, Texas, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Brown Deer, Wisconsin, United States
09

References and documents

Publications

  • Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020 Feb 15;263:258-266. doi: 10.1016/j.jad.2019.11.074. Epub 2019 Nov 13. PubMed 31818787 ↗
  • Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015 May;76(5):575-82. doi: 10.4088/JCP.14m09335. PubMed 26035185 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2010
First posted
Jul 15, 2010
Start
Jul 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01163266
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 15, 2010
Start date
Jul 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion